A big price target upgrade has this stock soaring

What you need to know                                                                                                                                                                                                                                                                                                                                                                                                                 April 25, 2024 A big price target upgrade has this stock soaring Good morning, 360! We have a jammed-packed day in the [Market Master’s Room]( including bonus teaching at 12EST and an exclusive CEO interview at 1EST. Drop by all day — Be the best prepared trader on the Street! FOCUS LIST🔎 PCSA - Up over 40% in pre after HC Wainwright initiates buy rating, $8 price target CDTX - Up over 24% in pre after $240 million private placement reacquisition of influenza treatment  ULBI - Up over 10% in pre after reporting better than expected earnings *sponsored by Sica Media Pull up Anixa Biosciences (ANIX) on your platform right now and take a look. Anixa is a clinical-stage biotech company that focuses on the treatment and prevention of cancer – that’s right, the prevention of cancer. Looking at its chart, it is not the typical “Gamma Trigger” setup I look for (though it might be forming), but rather a different clue that a lot of investors don’t pay enough attention to. Simply look at the volume… Small stocks like this are easy to spot volume spikes. If you look at last month, that early reading on increased volume led to a 30% surge over a few days. Volume can signal two different things. When you see a big volume spike in selling (like META today) there is clearly panic from investors as they are changing their mind on the direction of the stock.  On the other hand, a volume surge coupled with a rising stock price is an excellent “tell” by the market that investors are starting to pile back into a stock. When it comes to smaller stocks like ANIX, that is one of the top things I look for to spot potential moves. You saw it happen last month, and we just saw it for the first day yesterday as well. Do your own research on the stock and always approach your trading in a responsible manner. Trading is very risky and nothing is ever guaranteed, so never trade with more than you can afford to lose, and always have a well-thought-out game plan. *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. HOTLIST🔥 PCSA - Up over 40% in pre after HC Wainwright initiates buy rating, $8 price target Processa Pharmaceuticals, Inc. (PCSA) is a clinical stage pharmaceutical company that focuses on developing chemotherapy drugs to improve the safety and efficacy of cancer treatment. In the pre-market this morning [HC Wainwright initiated]( PCSA with a buy rating and $8 price target. The stock traded up over 40% in the pre-market in reaction to the news. The $2.11 area acted as support in the pre-market and will be an important level to watch. Above it, the first major target for bulls is the pre-market high at $2.38. Beyond that, targets are $2.60, $3 and $3.17. Below $2.11, targets to the downside are $2.02, $1.90, $1.80, and then a gap fill at $1.62. CDTX - Up over 24% in pre after $240 million private placement reacquisition of influenza treatment Cidara Therapeutics Inc. (CDTX) is a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. In the after-hours yesterday, the [company announced]( it had reacquired the global development and commercial rights to cd388 and announces a private placement financing of $240 million. CD388 is active against all strains of influenza A and B and is being developed for pre-exposure prophylactic treatment. The $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial. In exchange for reacquiring the exclusive global development and commercial rights to CD388, Johnson & Johnson has received from Cidara a one-time upfront payment of $85 million and is eligible to receive potential additional development, regulatory, and commercial milestone payments. CDTX also [announced]( that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of Rezafungin with an estimated approximately $128 million in cost savings. The stock traded up over 24% in the pre-market in reaction to the news. The $14.25 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $15, $16, $17.50 and then the after-hours high at $18.79. Below $14.25, targets to the downside are $13 and then a gap fill at $12.29. Small Account Journey  Join Jason as he teaches his favorite strategy to pursue his mission of turning $2000 into $100,000.  He won’t rest until he achieves that holy grail!  [Huge Special /Limited Seats Available]( → use code SAVE50 and Hit Apply ULBI - Up over 10% in pre after reporting better than expected earnings Ultralife Corporation (ULBI) designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. In the pre-market this morning, [ULBI reported]( Q1 2024 earnings. Highlights include : Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market sales Gross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarter GAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarter Adjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last year Backlog of $97.4 million exiting the 2024 first quarter The stock traded up over 10% in the pre-market in reaction to the earnings report. $9.76 acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $10.50 and then the pre-market high at $10.99. Beyond that, $11.50 and $11.85 come into play, above which is all-time highs at $11.97. Below $9.76, targets to the downside are $9 and then a gap fill $8.73. MARKET NEWS 📰 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America